BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16009165)

  • 1. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.
    Wilcox J; Potter D; Moore M; Ferrande L; Kelly E;
    Fertil Steril; 2005 Jul; 84(1):108-17. PubMed ID: 16009165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
    Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.
    Lee TH; Lin YH; Seow KM; Hwang JL; Tzeng CR; Yang YS
    Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
    Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
    Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction.
    Sauer MV; Thornton MH; Schoolcraft W; Frishman GN
    Reprod Biomed Online; 2004 Nov; 9(5):487-93. PubMed ID: 15588464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study.
    Lin YH; Wen YR; Chang Y; Seow KM; Hsieh BC; Hwang JL; Tzeng CR
    Fertil Steril; 2010 Jun; 94(1):179-83. PubMed ID: 19339001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?
    Chen HJ; Lin YH; Hsieh BC; Seow KM; Hwang JL; Tzeng CR
    J Assist Reprod Genet; 2006 Jun; 23(6):289-92. PubMed ID: 16865530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a lower-dose cetrorelix acetate protocol on in-vitro fertilization outcome.
    Tzeng CR; Chen HJ; Lin YH; Hsieh BC; Huang LW; Hwang JL
    Int J Gynaecol Obstet; 2008 Mar; 100(3):271-4. PubMed ID: 18045601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends.
    Checa MA; Prat M; Robles A; Carreras R
    Fertil Steril; 2006 Mar; 85(3):573-7. PubMed ID: 16500321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents?
    Griesinger G; Felberbaum RE; Schultze-Mosgau A; Diedrich K
    Drugs; 2004; 64(6):563-75. PubMed ID: 15018588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
    Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes.
    Kerimoğlu OS; Ercan CM; Keskin U; Korkmaz C; Duru NK; Ergün A
    Arch Gynecol Obstet; 2013 Sep; 288(3):691-5. PubMed ID: 23525593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study.
    Han EJ; Lyu SW; Kwak IP; Kwon H; Choi DH; Kim JY; Park HM; Kim JW; Chang EM; Lee HJ; Kim MK; Lee HN; Kim JY; Park S; Lee WS
    J Obstet Gynaecol; 2022 Aug; 42(6):2197-2202. PubMed ID: 35254199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
    Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
    J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
    Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
    Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles.
    Hwang JL; Huang LW; Hsieh BC; Tsai YL; Huang SC; Chen CY; Hsieh ML; Chen PH; Lin YH
    Hum Reprod; 2003 Jan; 18(1):45-9. PubMed ID: 12525439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.